Diabetes (type 2) - empagliflozin [ID641]: appraisal consultation
This page was last updated: 27 August 2014
|Closing date for invited submissions / evidence submission:||23 April 2014|
|1st appraisal committee meeting:||29 July 2014|
|2nd appraisal committee meeting||25 November 2014|
|Technical Lead:||Anwar Jilani|
|Communications manager:||Elizabeth Adelanwa|
In the Appraisal Consultation Document (ACD) for the appraise of empagliflozin combination therapy for treating type 2 diabetes [ID641], the Appraisal Committee requested further analyses from the company.
Boehringer Ingelheim has indicated that new economic analyses will be submitted in response to this request. In order to allow a complete set of analyses as requested by the Committee to be produced, and for those analyses to be reviewed by the Evidence Review group, NICE has agreed an extension in timings. Therefore the second Committee Meeting has been rescheduled to 25 November 2014.